(IPX) IperionX American - Overview
Sector: Basic Materials | Industry: Other Industrial Metals & Mining | Exchange: NASDAQ (USA) | Market Cap: 993m USD | Total Return: 138.4% in 12m
Titanium, Zircon, Rare Earths, Metal Powder
Total Rating 46
Safety 71
Buy Signal 0.07
Other Industrial Metals & Mining
Industry Rotation: +6.7
Industry Rotation: +6.7
Market Cap:
993M
Avg Turnover: 10.0M USD
Avg Turnover: 10.0M USD
ATR:
9.94%
Peers RS (IBD): 23.3
Peers RS (IBD): 23.3
Risk 5d forecast
Volatility107%
Rel. Tail Risk-6.88%
Reward TTM
Sharpe Ratio1.35
Alpha68.67
Character TTM
Beta1.459
Beta Downside2.057
Drawdowns 3y
Max DD65.86%
CAGR/Max DD1.21
Warnings
Interest Coverage Ratio -80.2 is critical
Altman Z'' -1.88 < 1.0 - financial distress zone
Volatile
Tailwinds
No distinct edge detected
Description: IPX IperionX American
IperionX Limited (NASDAQ: IPX) is a U.S.-based developer of critical mineral assets, holding 100 % of the Titan project in Tennessee, which hosts titanium, zircon, and rare-earth resources. The firm also manufactures angular and spherical titanium metal powders for a broad set of end-markets, including automotive, aerospace, defense, energy, medical, consumer electronics, luxury goods, and industrial applications.
As of the latest Q2 2024 update, the Titan project disclosed measured and indicated resources of approximately 1.2 million tonnes of ilmenite-equivalent titanium, while titanium powder demand in the U.S. automotive sector rose 12 % year-over-year, driven by lightweight-vehicle initiatives. Concurrently, the U.S. Department of Energy has earmarked $150 million in 2024 for domestic critical-minerals supply chain development, underscoring a favorable policy backdrop for IPX’s assets.
For deeper analysis, consider checking ValueRay’s platform.
- Titanium metal powder production volume and sales prices
- Critical minerals project development and permitting progress
- Raw material costs for titanium and rare earth elements
- Demand for titanium across aerospace and automotive sectors
- Regulatory changes impacting critical minerals extraction
Piotroski VR‑10 (Strict)
1.5
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.81 > 0.02 and ΔFCF/TA -77.77 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.18 > 3% & CFO -23.9m > Net Income -105.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.36m) vs 12m ago -87.57% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -80.24 > 6 (EBITDA TTM -110.3m / Interest Expense TTM 1.44m) |
Altman Z''
-1.88
| A: 0.40 (Total Current Assets 69.6m - Total Current Liabilities 17.3m) / Total Assets 129.2m |
| B: -1.11 (Retained Earnings -144.0m / Total Assets 129.2m) |
| C: -0.94 (EBIT TTM -115.2m / Avg Total Assets 122.5m) |
| D: 5.16 (Book Value of Equity 108.2m / Total Liabilities 21.0m) |
| Altman-Z'' Score: -1.88 = D |
What is the price of IPX shares?
As of April 09, 2026, the stock is trading at USD 30.95 with a total of 274,488 shares traded.
Over the past week, the price has changed by +11.89%, over one month by -35.21%, over three months by -28.51% and over the past year by +138.44%.
Over the past week, the price has changed by +11.89%, over one month by -35.21%, over three months by -28.51% and over the past year by +138.44%.
Is IPX a buy, sell or hold?
IperionX American has received a consensus analysts rating of 5.00.
Therefore, it is recommended to buy IPX.
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IPX price?
| Analysts Target Price | 55.6 | 79.6% |
IperionX American (IPX) - Fundamental Data Overview
as of 09 April 2026
P/E Forward = 1666.6667 P/B = 8.5503
Revenue TTM = 0.0 USD
EBIT TTM = -115.2m USD
EBITDA TTM = -110.3m USD
Long Term Debt = 9.39k USD (from longTermDebt, last quarter)
Short Term Debt = 1.11m USD (from shortTermDebt, last quarter)
Debt = 4.46m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -61.4m USD (from netDebt column, last quarter)
Enterprise Value = 931.9m USD (993.3m + Debt 4.46m - CCE 65.8m)
Interest Coverage Ratio = -80.24 (Ebit TTM -115.2m / Interest Expense TTM 1.44m)
EV/FCF = -8.95x (Enterprise Value 931.9m / FCF TTM -104.1m)
FCF Yield = -11.17% (FCF TTM -104.1m / Enterprise Value 931.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.41m) / Revenue TTM)
Tobins Q-Ratio = 7.22 (Enterprise Value 931.9m / Total Assets 129.2m)
Interest Expense / Debt = 32.14% (Interest Expense 1.43m / Debt 4.46m)
Taxrate = 21.0% (US default 21%)
NOPAT = -91.0m (EBIT -115.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.03 (Total Current Assets 69.6m / Total Current Liabilities 17.3m)
Debt / Equity = 0.04 (Debt 4.46m / totalStockholderEquity, last quarter 108.2m)
Debt / EBITDA = 0.56 (negative EBITDA) (Net Debt -61.4m / EBITDA -110.3m)
Debt / FCF = 0.59 (negative FCF - burning cash) (Net Debt -61.4m / FCF TTM -104.1m)
Total Stockholder Equity = 96.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -86.13% (Net Income -105.5m / Total Assets 129.2m)
RoE = -109.5% (Net Income TTM -105.5m / Total Stockholder Equity 96.4m)
RoCE = -119.5% (out of range, set to none) (EBIT -115.2m / Capital Employed (Equity 96.4m + L.T.Debt 9.39k))
RoIC = -83.54% (negative operating profit) (NOPAT -91.0m / Invested Capital 108.9m)
WACC = 11.18% (E(993.3m)/V(997.7m) * Re(11.12%) + D(4.46m)/V(997.7m) * Rd(32.14%) * (1-Tc(0.21)))
Discount Rate = 11.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -59.97%
[DCF] Fair Price = unknown (Cash Flow -104.1m)
EPS Correlation: 24.12 | EPS CAGR: 91.44% | SUE: 0.83 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS current Year (2026-06-30): EPS=-1.16 | Chg7d=-1.045 | Chg30d=-1.084 | Revisions Net=-1 | Growth EPS=-862.5% | Growth Revenue=+0.0%
EPS next Year (2027-06-30): EPS=-0.28 | Chg7d=-0.294 | Chg30d=-0.341 | Revisions Net=+0 | Growth EPS=+75.9% | Growth Revenue=+1190.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Current Year)
External Resources